H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Perspective Therapeutics, Inc. announced the dosing of the first patient in a new cohort of its Phase 1/2a trial assessing the safety of [212Pb]VMT01, a targeted alpha-particle therapy for ...

The new generator technology, developed internally by Telix’s IsoTherapeutics team, produces 212Pb via a sealed Thorium-228 (228Th) source, and significantly increases the amount of ...

The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is ...

both companies to co-develop four 212Pb-based RDT candidates, including MP0712 MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual ...